期刊文献+

孚来迪治疗2型糖尿病疗效观察 被引量:1

原文传递
导出
摘要 目的探讨孚来迪治疗2型糖尿病的效果。方法80例2型糖尿病患者采用孚来迪1.5-16 mg餐前口服,进餐服药,不进餐不服药,加餐则加服一次,疗程12周,观察治疗前后疗效比较。结果治疗12周后患者空腹血糖、餐后2 h血糖、糖化血红蛋白均有显著下降(P〈0.01),甘油三酯水平显著下降(P〈0.01),胆固醇的指标有轻度下降,但差异无统计学意义。C肽水平较治疗前下降(P〈0.05)。结论孚来迪起效快、作用强、作用时间短、代谢清除快,可作为治疗2型糖尿病的一线用药。
作者 寿砚芸
出处 《临床医学》 CAS 2007年第12期49-50,共2页 Clinical Medicine
  • 相关文献

参考文献3

  • 1Plosker GL, Figgitt DP. Repaglinide : a phamacoeconomic review of its use type 2 diabetes mellitus [ J ]. Phamacoeconanics, 2002, 22 ( 6 ) : 389 - 411.
  • 2Owens DR . Repaglinide -prandial glucose regulator: a new class of oral antidiabetic drugs [ J ]. Diabet Med, 1998,15 ( 4 ) : 28 - 36.
  • 3杨华章,陈亮,崔炎棠.降糖新药瑞格列奈的研究进展[J].中国实用内科杂志,2000,20(4):253-254. 被引量:32

二级参考文献15

  • 11,Fuhlendorff J,Rorsman P,Kofod H et al.Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinet processes.Diabetes,1998;47(3):345
  • 22,Owens DR.repaglinide-prandial glucose regulator:a new class of oral antidiabetic drugs.Diabet Med,1998;15suppl(4):S28
  • 33,John R,White Jr,Pharm D.The pharmacological reduction of blood glucose in patients with type 2 diabetes melitus.Clinical Diabetes,1998;16:2
  • 44 Polonsky KS,Sturis J,Bell CI.Seminars in Medicine of the Beth Israel Hospital,Boston.Non-insulin-dependent diabetes melitus-a genetically programmed failure of the beta cell to compensate for insulin resistance.N Engl J Med,1996;334(12):777
  • 55,P J Lefebvre,Scheen AJ.The postprandial state risk of cardiovascular disease.Diabet Med,1998;15(Suppl 4):S63
  • 66,Goldberg,Einhorn D,Lucas CP,et al.A randomized placebocontrolled trial of repaglinide in the teatment of type 2 diabetes.Diabetes Care,1998;21(11):1897
  • 77,Landgraf R,Bilo HJ.A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.1999;55(3):165
  • 88,Wolffenbuttel BH,LandgrafR.A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes.Dutch and German repaglinide Study Group Diabetes Care,1999;22(3):463
  • 99,alfour JA,Faulds D.repaglinide.Drugs Aging,1998;13(2):173
  • 1010,Owens DR.Repaglinide:a new short-acting insulinotropic agent for the treatment of type 2 diabetes.Eur J Cling Invest,1999;29Suppl2(1):30

共引文献31

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部